comparemela.com

Latest Breaking News On - Oncology for early clinical research - Page 1 : comparemela.com

Checkmate Pharmaceuticals Welcomes Industry Leader Jon

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical.

United kingdomUnited statesSutro biopharmaAlan fuhrmanJon wiggintonBristol myers squibbOncology for early clinical researchCheckmate pharmaceuticals incSociety for immunotherapy of cancerNational cancer instituteClinical oncology at merck research laboratoriesCullinan oncology incUniversity of michiganExchange commissionCancer researchAvailability of other information about checkmate pharmaceuticals

Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M D to its Board of Directors

31.01.2022 - CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) - Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system . Seite 1

United statesSutro biopharmaBristol myers squibbCancer researchOncology for early clinical researchSociety for immunotherapy of cancerNational cancer instituteClinical oncology at merck research laboratoriesCullinan oncology incUniversity of michiganSenior advisorCullinan oncologyMedical officerChief medical officerTherapeutic area headEarly clinical research

vimarsana © 2020. All Rights Reserved.